Review anchor
Sodium channel protein type 8 subunit alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Sodium channel protein type 8 subunit alpha
CHEMBL5202
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sodium channel protein type 8 subunit alpha as ChEMBL target CHEMBL5202, mapped to UniProt Q9UQD0. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5202
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9UQD0
Sodium channel protein type 8 subunit alpha
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Sodium channel protein type 8 subunit alpha matters
Sodium channel protein type 8 subunit alpha is reviewed as Sodium channel protein type 8 subunit alpha (UniProt Q9UQD0); Sodium channel protein type 8 subunit alpha shows clinical signal disease relevance led by Seizure.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 1171 compounds, and 129 assays, with lead potency reaching pChEMBL 10.2.
Protein context
Sodium channel protein type 8 subunit alpha
Sodium channel protein type 8 subunit alpha Sequence length is 1980 aa.
Review this target as Sodium channel protein type 8 subunit alpha, mapped to UniProt Q9UQD0. Sequence length is 1980 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9UQD0
Protein
Disease context
Seizure
Sodium channel protein type 8 subunit alpha shows clinical signal disease relevance led by Seizure. 1 linked drug keep the rationale reviewable. Linked drugs include ZANDATRIGINE.
Start review with Seizure because it currently carries clinical signal support. Linked drugs include ZANDATRIGINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 1171 compounds, and 129 assays for this target. The dominant activity type is IC50. CHEMBL4061793 is the current potency anchor at pChEMBL 10.2.
Use CHEMBL4061793 as the tractability anchor when discussing potency (pChEMBL 10.2).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 10.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Sodium channel protein type 8 subunit alpha matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9UQD0, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why Seizure is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1171
Total Compounds
129
Total Assays
1
Approved Drugs
IC50: 2070.0, EC50: 9.0, KD: 12.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4061793
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL4062780
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL3617063
|
9.1 | IC50 | — |
|
|
No preferred name
CHEMBL3678273
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL5742330
|
9.0 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
TETRACAINE
CHEMBL698
|
2005 |
Source Header